UB Paderborn / Katalog / Suche / in CDI

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

PloS one, 2018-09, Vol.13 (9), p.e0202753

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

The Journal of infectious diseases, 2011-03, Vol.203 (5), p.610-619

2011

Link zum Volltext

Verfügbarkeit prüfen

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review

PloS one, 2013-01, Vol.8 (1), p.e54407

2013

Link zum Volltext

Verfügbarkeit prüfen

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

The Journal of infectious diseases, 2014-07, Vol.210 (1), p.99-110

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults

PloS one, 2012-01, Vol.7 (1), p.e29231

2012

Link zum Volltext

Verfügbarkeit prüfen

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

The Journal of infectious diseases, 2019-05, Vol.219 (11), p.1755-1765

2019

Link zum Volltext

Verfügbarkeit prüfen

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

Clinical and vaccine immunology, 2016-06, Vol.23 (6), p.496-506

2016

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

Open forum infectious diseases, 2015-09, Vol.2 (3), p.ofv082-ofv082

2015

Link zum Volltext

Verfügbarkeit prüfen

Patients in Long-Term Care Facilities: A Reservoir for Vancomycin-Resistant Enterococci

Clinical infectious diseases, 2002-02, Vol.34 (4), p.441-446

2002

Link zum Volltext

Verfügbarkeit prüfen

Safety profile of recombinant canarypox HIV vaccines

Vaccine, 2004-01, Vol.22 (5-6), p.704-713

2004

Link zum Volltext

Verfügbarkeit prüfen

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

The Journal of infectious diseases, 2013-09, Vol.208 (5), p.818-829

2013

Link zum Volltext

Verfügbarkeit prüfen

A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers

The Journal of infectious diseases, 2011-04, Vol.203 (8), p.1165-1173

2011

Link zum Volltext

Verfügbarkeit prüfen

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

PloS one, 2010-08, Vol.5 (8), p.e11995

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

Vaccine, 2009-01, Vol.27 (2), p.243-249

2009

Link zum Volltext

Verfügbarkeit prüfen

Progress in the development of a preventive HIV-1 vaccine

Clinics in Laboratory Medicine, 2002-12, Vol.22 (4), p.963-980

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

Clinical and vaccine immunology, 2014-11, Vol.21 (11), p.1589-1599

2014

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 Vaccination Administered Intramuscularly Can Induce Both Systemic and Mucosal T Cell Immunity in HIV-1-Uninfected Individuals

The Journal of immunology (1950), 2003-07, Vol.171 (2), p.1094-1101

2003

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis c virus-specific cytolytic t cell responses after antiviral therapy

Clinical immunology (Orlando, Fla.), 2003-09, Vol.108 (3), p.211-220

2003

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

Patients in Long-Term Care Facilities: A Reservoir for Vancomycin-Resistant Enterococci

Safety profile of recombinant canarypox HIV vaccines

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial

Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 + T-Cell Responses by Interleukin-12 Plasmid DNA

A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

Robust antibody and cellular responses induced by DNA-only vaccination for HIV

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

Progress in the development of a preventive HIV-1 vaccine

Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP ® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

HIV-1 Vaccination Administered Intramuscularly Can Induce Both Systemic and Mucosal T Cell Immunity in HIV-1-Uninfected Individuals

Hepatitis c virus-specific cytolytic t cell responses after antiviral therapy

Suchergebnisse filtern